From DCAT Value Chain Insights (VCI)
Douglas Williams, PhD, currently executive vice president of research and development at Biogen will leave the company at the end of July to become CEO of as-yet unnamed start-up biotechnology company. Dr. Williams will be the first member of a new organization with potential in cancer diagnostics and therapy.
Responsibility for Biogen Research and Development will be assumed by Alfred Sandrock, MD, PhD., senior vice president and chief medical officer, and Spyros Artavanis-Tsakonas, PhD, senior vice president and chief scientific officer. Both Dr. Sandrock and Dr. Artavanis-Tsakonas currently serve on the executive management team of the company.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription